Publish or perish

Article

In ophthalmology, particular emphasis is placed on clinical research and publications in order to gain entrance to higher specialist training. However, the length of time from submission of an article to a committee for review through to its publication, has often acted as a deterrent to many people who just want their voice to be heard As a result, concerns were raised that the length of time and administration costs of completing this process may result in a decrease in publications by junior doctors.1,2

Moreover, scientific and clinical productivity in the form of research projects and clinical case report publications to journals is commonly considered an accurate measure on which to base career advancement. Hence, there was a great concern than the future generation of ophthalmologists would not be able to progress past a certain level because of the difficulties they may find in having their research published.

In 1997, UK multicentre research ethics committees were introduced in a bid to overcome difficulties with applications to multiple local committees. This was followed by the introduction, in 2004, of the new Central Office for Research Ethics Committees (COREC).

Have article submission patterns changed?

Case reports dominate

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.